PMID- 1382813
OWN - NLM
STAT- MEDLINE
DCOM- 19921125
LR  - 20190613
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 589
IP  - 2
DP  - 1992 Sep 4
TI  - Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane 
      (para-methoxymethamphetamine, PMMA).
PG  - 349-52
AB  - These studies assessed the neurotoxic potential of 
      N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine; PMMA), 
      an amphetamine analog that has surfaced in the illicit drug market. Repeated 
      subcutaneous injections of PMMA caused lasting, dose-related reductions in 
      regional brain concentrations of serotonin (5-HT) and 5-hydroxyindoleacetic acid 
      (5-HIAA), and in the density of [3H]paroxetine-labelled 5-HT uptake sites. 
      Comparison of the neurotoxic potential of PMMA to that of para-methoxyamphetamine 
      (PMA) and 3,4-methyl-enedioxymethamphetamine (MDMA) showed that equivalent doses 
      of PMMA and PMA (80 mg/kg) produced comparable depletions of 5-HT, but that these 
      depletions were not as pronounced as those induced by a lower dose of MDMA (20 
      mg/kg). Striatal DA was not affected on a long-term basis by any of the 
      ring-substituted amphetamines evaluated in this study. These data suggest that 
      PMMA, like PMA and MDMA, produces long-term (possibly neurotoxic) effects on 
      brain serotonin neurons, but that PMMA is less potent than MDMA as a 5-HT 
      neurotoxin. Further, they raise concern over the illicit use of PMMA since humans 
      could be more sensitive than rodents to the 5-HT neurotoxic effects of PMMA and 
      related drugs.
FAU - Steele, T D
AU  - Steele TD
AD  - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
      MD 21224.
FAU - Katz, J L
AU  - Katz JL
FAU - Ricaurte, G A
AU  - Ricaurte GA
LA  - eng
GR  - DA 06275/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Amphetamines)
RN  - 0 (Hallucinogens)
RN  - 037U5SR9KL (4-methoxymethamphetamine)
RN  - 333DO1RDJY (Serotonin)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OVB8F8P39Q (4-methoxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/toxicity
MH  - Amphetamines/toxicity
MH  - Animals
MH  - Brain Chemistry/drug effects
MH  - Hallucinogens/toxicity
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Male
MH  - Methamphetamine/*analogs & derivatives/toxicity
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Nervous System Diseases/*chemically induced/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/metabolism
MH  - Structure-Activity Relationship
EDAT- 1992/09/04 00:00
MHDA- 1992/09/04 00:01
CRDT- 1992/09/04 00:00
PHST- 1992/09/04 00:00 [pubmed]
PHST- 1992/09/04 00:01 [medline]
PHST- 1992/09/04 00:00 [entrez]
AID - 0006-8993(92)91298-S [pii]
AID - 10.1016/0006-8993(92)91298-s [doi]
PST - ppublish
SO  - Brain Res. 1992 Sep 4;589(2):349-52. doi: 10.1016/0006-8993(92)91298-s.